Savient Pharmaceuticals Overview
- Year Founded
-
1980
- Status
-
Acquired/Merged
- Employees
-
122
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
4
- Investments
-
2
Savient Pharmaceuticals General Information
Description
Operator of a specialty biopharmaceutical company. The company and its subsidiaries are focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets.
Contact Information
Website
www.savientpharma.comCorporate Office
- 400 Crossing Boulevard
- Bridgewater, NJ 08807
- United States
Corporate Office
- 400 Crossing Boulevard
- Bridgewater, NJ 08807
- United States
Savient Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Savient Pharmaceuticals Patents
Savient Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2010151823-A1 | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy | Inactive | 25-Jun-2009 | ||
| AU-2010265879-A1 | Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout | Inactive | 25-Jun-2009 | ||
| CA-2764761-A1 | Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout | Inactive | 25-Jun-2009 | ||
| EP-2445514-A1 | Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout | Inactive | 25-Jun-2009 | ||
| US-20120323107-A1 | Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout | Inactive | 25-Jun-2009 | G01N33/6893 |
Savient Pharmaceuticals Signals
Savient Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Savient Pharmaceuticals Investments & Acquisitions (2)
Savient Pharmaceuticals’s most recent deal was a Merger/Acquisition with Myelos Neurosciences for . The deal was made on 19-Mar-2001.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Myelos Neurosciences | 19-Mar-2001 | Merger/Acquisition | Therapeutic Devices | ||
| Omrix Biopharmaceuticals | 04-Sep-1999 | Early Stage VC | Biotechnology |
Savient Pharmaceuticals Exits (1)
Savient Pharmaceuticals’s most recent exit was on 04-Sep-1999 from Omrix Biopharmaceuticals. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Omrix Biopharmaceuticals | 04-Sep-1999 | Completed |
|
Savient Pharmaceuticals FAQs
-
When was Savient Pharmaceuticals founded?
Savient Pharmaceuticals was founded in 1980.
-
Where is Savient Pharmaceuticals headquartered?
Savient Pharmaceuticals is headquartered in Bridgewater, NJ.
-
What is the size of Savient Pharmaceuticals?
Savient Pharmaceuticals has 122 total employees.
-
What industry is Savient Pharmaceuticals in?
Savient Pharmaceuticals’s primary industry is Buildings and Property.
-
Is Savient Pharmaceuticals a private or public company?
Savient Pharmaceuticals is a Private company.
-
What is the current valuation of Savient Pharmaceuticals?
The current valuation of Savient Pharmaceuticals is .
-
What is Savient Pharmaceuticals’s current revenue?
The current revenue for Savient Pharmaceuticals is .
-
Who are Savient Pharmaceuticals’s investors?
Franklin Templeton, Palo Alto Investors, and Wellington Management have invested in Savient Pharmaceuticals.
-
When was Savient Pharmaceuticals acquired?
Savient Pharmaceuticals was acquired on 13-Jan-2014.
-
Who acquired Savient Pharmaceuticals?
Savient Pharmaceuticals was acquired by Crealta Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process